Metabolism Management

Estimated reading time: 5 minutes

The first honest AI governance move isn’t regulating models. It’s an institution admitting it can’t yet measure what it’s absorbing.

Adoption announcements are easy. Absorption meters are rare. Most AI programs track licenses, pilots, and model vendors. Few can say what evidence would prove the last major AI capability is ready for the next class of consequence.

Deployment asks whether people have the tool. Usage asks whether they use it. Absorption asks whether the organization can safely act on what it produces. Metabolism Management is the discipline of preventing AI capability from moving into a higher-stakes class of use faster than the organization can prove it knows how to absorb its outputs.

When the Tool Surfaces What You Cannot Trust

During a period of rapid AI tool rollout, one of the search tools we had already approved started surfacing wrong answers in high-stakes work. It was pulling from unvalidated internal documents, including inaccurate claims about prior delivery. When the next decision depends on verified facts, an unverified claim is a credibility problem, not a typo. Leadership could not yet measure how much of what the tool surfaced was actually reliable. That uncertainty was the real risk, not the tool itself.

We did not ban it, and we did not wave it through. The call was to pause its extension into higher-stakes workflows until there was a way to validate what it could draw from. Fix what feeds it before letting it feed more.

I owned the fix. I had already been building a content registry: a structured, version-controlled layer where every piece of source material carried a review status and a clear origin. That registry became the gate. The tool would only pull from content that had been checked, not raw, unvetted material. Building the registry produced a second benefit: once validated work was structured consistently, repeated capabilities that had previously looked like isolated projects became visible as patterns. A partner team engaged to help extend the approach. Deeper technical work got scheduled to integrate the registry with the broader AI tooling before anyone expanded use further.

The registry was our instrument, not the principle. Another AI system might require evaluation suites, review pass rates, attested inputs, override logging, or explicit use boundaries. Metabolism Management asks the same question in each case: what evidence must exist before this capability is allowed to move into the next stake class?

An absorption metric is the evidence that consequential work can rely on the output. For search or retrieval, it might be the share of answers that cite only approved sources, or the rate of claimed facts that fail verification in high-stakes drafts. For code assistants, it might be suggested changes that pass review without silent security or contract regressions. For decision support, it might be recommendations where a named owner can attest the inputs and the override path. Deployment counts licenses. Absorption measures whether the next consequential decision can safely rely on what the system produced.

Temporal’s CEO recently said the company 5x’d AI spend and roughly doubled revenue, then admitted he cannot prove the two are connected. That is an honest gap between usage and absorption. Velocity is easy to count. Evidence that the organization can safely escalate what the system produces is harder.

The same stake-class logic shows up outside the firm. New York State paused new hyperscale data centers for up to a year while it worked out how to measure their effects: refuse to escalate consequence before measurement capacity exists.

The Digestion Gap described the capacity problem: more enters than an organization can convert into action. Coordination Debt described the structural consequence: tools multiply faster than decision rights and handoffs can adapt. Metabolism Management is the governance response: control the rate at which new capability moves into consequential use.

The obvious danger is turning “absorption” into another review board. That would miss the point. The objective isn’t to slow experimentation uniformly. It is to separate experimentation from escalation. A team should be able to explore rapidly at low stakes while the burden of evidence rises with consequence.

Five Questions Before Your Next Escalation

Answer yes or no. No means a warning sign.

1. Can you name the metric showing whether your last major AI adoption has been absorbed rather than merely deployed?
2. Is there a defined trigger for pausing expansion when measurement capacity lags adoption?
3. Are the metrics aligned with the value actually being claimed (judgment, revenue, capacity, quality) rather than only efficiency?
4. Could leadership state what evidence would cause it to stop funding or expanding the AI initiative?
5. Is there a named owner with authority to slow expansion when absorption capacity is exceeded?

How to Read Your Score

0–1 no. Local gap. Map the weakest unmeasured escalation path this week and name its owner.

2–3 no. Metabolism Management is overdue. Before the next higher-stakes use case, write one page: the absorption metric, the pause trigger, and which low-stakes paths stay open while the meter is built.

4–5 no. Treat further high-stakes expansion as an exception requiring explicit justification. Establish the measurement owner, absorption metric, and pause trigger before adding another consequential use case. Keep low-stakes exploration if you must.

As stakes increase, the burden of evidence increases. More capacity is not the same as more metabolism.

What did your organization deploy last quarter that it still cannot prove it has absorbed?

Madam I’m Adam

This continues the thread from Coordination Debt and Designing for Absorption: capacity problem, then structural consequence, then the governance response.